5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Avidity Biosciences Inc. NASDAQ:RNA, a $6 billion market cap biotech company whose stock has surged nearly 60% year-to-date, reported that Chief Human Resources Officer Teresa McCarthy sold 10,000 shares of common stock on August 15, 2025, for a total of $465,632. The shares were sold at prices ranging from $45.36 to $47.50. According to InvestingPro analysis, the stock’s technical indicators suggest it’s currently in overbought territory.
The same day, McCarthy also exercised options to acquire 10,000 shares of Avidity Biosciences common stock at a price of $22.34 per share, for a total value of $223,400.
Following these transactions, McCarthy directly owns 97,130 shares of Avidity Biosciences, Inc.
The option exercise and subsequent stock sale were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 11, 2025.
In other recent news, Avidity Biosciences has completed enrollment for its global Phase 3 HARBOR clinical trial of delpacibart etedesiran for myotonic dystrophy type 1, with topline data expected in the second quarter of 2026. The company plans to submit marketing applications in the United States, European Union, and Japan starting in the second half of 2026. In another development, the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Avidity’s delpacibart zotadirsen for treating Duchenne muscular dystrophy, a move aimed at expediting the drug’s development and review. Meanwhile, Goldman Sachs has resumed coverage on Avidity Biosciences with a Buy rating, citing a positive outlook on the company’s platform technology. Cantor Fitzgerald also reiterated its overweight rating on Avidity, highlighting confidence in the company’s leadership and their efforts in developing treatments for rare muscle diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.